Moxifloxacin (M)

DRUG4 trials

Sponsors

Global Alliance for TB Drug Development, University College, London, Shenzhen Third People's Hospital, Wuhan Pulmonary Hospital

Conditions

Efficacy and SafetyPulmonary Tuberculosis

Phase 2

Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)

CompletedNCT01498419

Global Alliance for TB Drug DevelopmentPulmonary Tuberculosis

Start: 2012-03-31End: 2013-07-31Updated: 2018-06-28

Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

RecruitingNCT06114628

University College, LondonPulmonary Tuberculosis

Start: 2024-01-09End: 2027-08-11Target: 2500Updated: 2025-10-06

Phase 3

A PAN-USR TB Multi-Center Trial

RecruitingNCT06905522

Shenzhen Third People's HospitalPulmonary Tuberculosis

Start: 2025-06-18End: 2029-12-31Target: 610Updated: 2025-12-01

Unknown Phase

A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis

Not yet recruitingNCT07126639

Wuhan Pulmonary HospitalEfficacy and Safety

Start: 2025-09-01End: 2028-09-30Target: 200Updated: 2025-08-17

Related Papers

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.

2015-03-18185 citations

Potent Rifamycin-Sparing Regimen Cures Guinea Pig Tuberculosis as Rapidly as the Standard Regimen

Antimicrobial Agents and Chemotherapy2013-06-0430 citations